Siemens Makes Innovation Accessible with Comprehensive Molecular Imaging...( Customer-focused solutions in molecul...),Health

Customer-focused solutions in molecular imaging offer greater long-term value

TORONTO, June 13 /PRNewswire/ -- At the 2009 SNM Annual Meeting in Toronto this week, Siemens (booth #1024) is breaking down barriers to market entry, as well as offering versatile, multipurpose solutions that help physicians provide high quality patient care, and effectively manage healthcare costs. As the healthcare landscape changes within the United States and internationally, Siemens molecular imaging solutions offer options at all purchasing levels. The Biograph(TM) mCT, the world's first molecular CT, will be shown at SNM for the first time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

"Enabling our partners to maintain clinical viability and provide value to the patients they serve is critical to our mission during these challenging economic times. It is, therefore, imperative that we find a way to offer our customers both high-quality solutions and access to advanced technologies," said Michael Reitermann, chief executive officer, Molecular Imaging, Siemens Healthcare. "Though we've recently made some progress in U.S. imaging reimbursement policies, we need to further develop evidence-based data on a global level, so that we can continue to prove the clinical and financial efficacy of molecular imaging technology as a valuable asset to detect, stage and monitor disease."

As part of Siemens Molecular Imaging's commitment to innovation and access, it has recently released several new systems into the PET-CT and SPECT-CT markets that allow facilities with limited budgets, or those under financial constraints, to provide molecular imaging technology to their patients:

'/>"/>